Censo Bio is a specialist discovery services company using human iPSC to support neurodegenerative and neuro-inflammation focused discovery projects. Censo provides access to a diverse range of existing human iPSC lines, and ethically sources relevant human tissue, both healthy and with disease specific mutations, with which to custom generate new iPSC lines from large cohorts of individuals. We can gene edit these lines to knock in, knock out or correct target genes of interest, and have developed reproducible differentiation protocols for a number of lineages, including microglia, astrocytes, cortical, and sensory neurons. Using these cells for neurodegenerative and neuro-inflammatory disease discovery, we offer customisable phenotypic assays to deliver disease relevant compound characterisation, providing new insights and functional disease related understanding of our clients compounds. Our technology also enables the study of genotype-phenotype relationships in large populations, providing an understanding of patient population therapeutic response variability.
We custom develop robust and repeatable iPSC differentiation protocols that will work without further optimisation across multiple iPSC lines, focussed on compound screening applications.
As well as generating physiologically relevant cell types, we ensure our differentiation protocols address the challenges of cost, scale, repeatability, and robustness. Most importantly, we ensure that our protocols are optimised to create cells ready for use in relevant assay platforms and can tailor these to your specific needs. All protocols are stress tested to ensure they are consist using a single cell line multiple times and also work robustly with multiple cell lines, from both healthy and disease backgrounds. Protocols are fully documented in Standard Operating Procedures and used by multiple researchers before being assessed as robust. Often starting with protocols developed in academic research, we have “industrialised” protocols for the differentiation of many cell lineages.
Our current client collaborations focus on the generation of: - Tissue Resident Macrophage and Microglia - Sensory neurons - Cortical neurons - Astrocytes. Please get in touch to find out more about our capacity to produce these cell types or our ability to develop and refine other differentiation protocols specific to your needs.
Our dedicated pluripotent cell scientists are experts in the generation and cultivation of iPSCs. We offer the ability to generate large numbers of iPSC lines, either from samples supplied by clients, or specifically sourced by our biosample acquisition team from their wide clinical network. Furthermore, our in-house genome editing team have extensive experience in the creation of genetically modified iPSC lines, and work seamlessly with our cell production and quality control teams. Censo provides all aspects of pluripotent cell culture services including: -sample procurement from healthy and specific disease background donors - iPSC generation - Genome editing - iPSC line expansion and banking - iPSC line characterisation and safety testing - Custom product testing with pluripotent cells - Cryo-storage and distribution
At Censo, we support the development of new treatments for disease by creating iPSC lines from tissue samples procured from individuals with relevant genotypic or clinical backgrounds.
Using our capacity to generate large numbers of iPSC lines, we can create lines from individuals with a diverse variety of genetic backgrounds and varying clinical histories. By doing so, we provide researchers with powerful resources to investigate variations in disease phenotype and variations in drug efficacy across the population as a whole.
Our dedicated pluripotent cell scientists are experts in the generation and cultivation of induced pluripotent stem cells (iPSCs)
Furthermore, our in-house genome editing team have specific experience in the creation of high value genetically modified pluripotent stem cell lines and work seamlessly with our cell production and quality control teams.
Censo provides all aspects of pluripotent cell culture services including:
For differentiated disease relevant human iPSCs to provide new approaches to drug development, it is essential that they can be used in relevant phenotypic assays suitable for compound screening. Our assay development and compound screening resource is based at our Cambridge facility, and led by ex-pharma scientists with extensive experience of cell based compound screening. Working seamlessly with our iPSC production, gene editing and cell differentiation resources, our assay development and compound screening teams offer a fully integrated service to clients who wish to be at the forefront of iPSC based drug discovery. Using our human iPSC derived cells from healthy and specific disease populations we can custom build and validate iPSC-based cell models at scale to provide new insights and functional disease relevant understanding of our clients leads and drug candidates: - Wide range of endpoint detection systems available - Advice on best approaches to compound evaluation - Custom phenotypic assay development - Assay and target validation - Disease relevant compound characterisation Our technology also enables the study of genotype-phenotype relationships in large populations, providing an understanding of patient population therapeutic response variability. Our assay platform capabilities include: - Hamamatsu FDSS for compound activity on Calcium flux. - IncuCyte real time cell function imaginng. - ThermoFisherArray Scan VTI for high-content imaging e.g. phagocytosis, neurite outgrowth. - Agilent Seahorse for energy metabolism e.g. mitochondrial function assessment. - Bio-tekSynergyHT for luminescent, fluorescent and absorbance plate based assays e.g. cytokine release, intracellular signaling readouts. - Guava easycyteHT for flow cytometry to measure surface marker expression - Li-COR odyssey for western blot quantification - Quant studio 7 for qPCR analysis We can also offer electrophysiology, electrical field stimulation and MEA through collaborator network.
Lead Identification and Validation Services
Censo Biotechnologies has not received any reviews.
Censo Biotechnologies has not received any endorsements.